01/26/2025
Xu Lab 2025 News
Congratulations to Bohan and Chang on their paper, which was published in Scientific Reports. They found that Aurora Kinases upregulation after treatment with chemotherapy could confer chemotherapy resistance to TNBC cells, and AURKB could serve as preselection markers for stratifying patients for neoadjuvant chemotherapy, considering AURKB was found to be highly expressed in African American TNBC patients compared to European Americans.
4/15/2022
5/12/2023
11/18/2023
1/1/2024
1/18/2024
2/7/2024
2/9/2024
2/12/2024
10/24/2024
12/05/2024
Xu Lab 2022-2024 News
Our AKT PROTAC degrader story was covered by Oncology Tube media during AACR 2022
https://oncologytube.com/jia-xu-phd-icahnmountsinai-tischcancer-aacr22-cancer-degradation-of-akt-inhibits-tumor-growth/
Congratulations to Yuwei and Han!
The first generation of Xu Lab undergraduate trainees is ready to leave the base for their universe of science exploration. We want to express our profound congratulations to Yuwei and Han for their successful Ph.D. program application in 2023. Yuwei will become a graduate student at the University of Georgia, and Han will go to UC Davis for a great Biomedical Engineering Ph.D. program. We are proud of them and appreciate their achievement in our lab. Best wishes to Yuwei and Han for their future research endeavors!
The logo of Xu Lab is officially launched!
A brand new logo of Xu lab is officially launched on 11/18/2023! The logo reflects the essence of basic science research in finding the cure for cancer, as it is highly associated with the changes in DNA (“Double helix” – DNA), represents both genetics and epigenetics mutations, and also shows how genetics studies advance cancer treatment history.
Our group’s abstract entitled “Clinicopathologic Features and Response to Pembrolizumab Neoadjuvant Therapy in Triple Negative Breast Cancer (TNBC): A Single Institution Experience”, abstract ID 1373, was accepted for presentation in the United States and Canadian Academy of Pathology’s 113th Annual Meeting, March 23-28, 2024, in Baltimore, Maryland. Congratulations!
Congratulations to Zhiqian!
Big congratulations to Zhiqian for her successful admission to John Hopkins University and University of Pennsylvania MPA program in 2024. We are very happy that she chose to stay in USA and drop the offer from University College London. Best wishes to Zhiqian for her future endeavors and Look forward to a lab reunion in New England area!
Dr. Jia Xu has a new publication on JCI insight. Congratulations!
Dr. Xu has a new publication in JCI insight, discovering that differential histone acetylation and super-enhancer driven epigenetic regulation underlie melanoma cell dedifferentiation and caused transcriptome changes could be essential for future therapeutic targeting. Check out this hot paper coming out on the JCI website https://insight.jci.org/articles/view/166611
Congratulations to Jiuyi!
Big congratulations to Jiuyi for his successful admission to prestigious UCSF and UIUC Ph.D. program in 2024. Best wishes to Jiuyi for his future endeavors!
Our group’s abstract, “Aurora kinases inhibition enhances neoadjuvant chemotherapy response in Triple Negative Breast Cancer, " abstract ID LB061, was accepted for presentation at the AACR Annual Meeting, April 5-10, 2024, in San Diego, California. Congratulations!
Congratulations to Bohan for the three abstracts accepted for presentation at the 2025 USCAP meeting! Xu Lab and the Department of Genetics are well-represented in the United States and Canadian Academy of Pathology’s 114th Annual Meeting.
Abstract ID 2747 “Younger Age, HER2-positive and Triple-negative Status in Primary Breast Cancer Predict Shorter Onset of Brain Metastasis”.
Abstract ID 1661 “Significant Worse Progression Free Survival (PFS) in early-stage (pT1N0M0) Uterine Serous Carcinoma with HER2-positive and HER2-low Status: One institution’s experience”.
Abstract ID 859 “High Tumor Infiltrating Lymphocytes Are Significantly Associated with Increased Pathological Complete Response Rate in Patients with Triple Negative Breast Cancer and Treated with Neoadjuvant KEYNOTE 522 Chemoimmunotherapy”.
Check out the Genetics Roundtable Discussion from Dr. Jia Xu and Dr. Zhangli Su. Dr. Xu shares insights into his research, the inspirations behind his research path, and the potential impact of their findings on the future.
https://www.uab.edu/medicine/genetics/news-events/department-news/genetics-roundtable-su-xu
More news…
INews